Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer-Reference-Cited by-同舟云学术

Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer

Published:2019-01 Issue:1 Volume:152 Page:53-60
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

González Martín Antonio,Oza Amit M.,Embleton Andrew C.,Pfisterer Jacobus,Ledermann Jonathan A.^ORCID,Pujade-Lauraine Eric,Kristensen Gunnar^ORCID,Bertrand Monique A.,Beale Philip,Cervantes Andrés,Kent Emma,Kaplan Richard S.^ORCID,Parmar Mahesh K.B.,Scotto Nana,Perren Timothy J.

Funder

F. Hoffmann-La Roche Ltd

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference36 articles.

1. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

2. ICON7 investigators., A phase 3 trial of bevacizumab in ovarian cancer;Perren;N. Engl. J. Med.,2011

3. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer;Aghajanian;J. Clin. Oncol.,2012

4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial;Pujade-Lauraine;J. Clin. Oncol.,2014

5. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial;Coleman;Lancet Oncol.,2017

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial;Med;2024-08

2. The impact of varying levels of residual disease following cytoreductive surgery on survival outcomes in patients with ovarian cancer: a meta-analysis;BMC Women's Health;2024-03-15

3. Tissue Inhibitor of Metalloproteinase 3: Unravelling Its Biological Function and Significance in Oncology;International Journal of Molecular Sciences;2024-03-10

4. Olaparib plus bevacizumab as a first-line maintenance treatment for patients with advanced ovarian cancer by molecular status: an updated PAOLA-1 based cost-effectiveness analysis;Journal of Gynecologic Oncology;2024

5. AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trial;International Journal of Gynecologic Cancer;2023-11-07